Kunos G - Search Results

1

Renal Mitochondrial ATP Transporter Ablation Ameliorates Obesity-Induced CKD.

Permyakova A, Hamad S, Hinden L, Baraghithy S, Kogot-Levin A, Yosef O, Shalev O, Tripathi MK, Amal H, Basu A, Arif M, Cinar R, Kunos G, Berger M, Leibowitz G, Tam J. Permyakova A, et al. Among authors: kunos g. J Am Soc Nephrol. 2024 Mar 1;35(3):281-298. doi: 10.1681/ASN.0000000000000294. Epub 2024 Jan 11. J Am Soc Nephrol. 2024. PMID: 38200648

2

Endocannabinoids in liver disease.

Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, Kunos G. Tam J, et al. Among authors: kunos g. Hepatology. 2011 Jan;53(1):346-55. doi: 10.1002/hep.24077. Hepatology. 2011. PMID: 21254182 Free PMC article. Review.

3

The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications.

Kunos G, Tam J. Kunos G, et al. Br J Pharmacol. 2011 Aug;163(7):1423-31. doi: 10.1111/j.1476-5381.2011.01352.x. Br J Pharmacol. 2011. PMID: 21434882 Free PMC article. Review.

4

Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.

Tam J, Godlewski G, Earley BJ, Zhou L, Jourdan T, Szanda G, Cinar R, Kunos G. Tam J, et al. Among authors: kunos g. Am J Physiol Endocrinol Metab. 2014 Feb 15;306(4):E457-68. doi: 10.1152/ajpendo.00489.2013. Epub 2013 Dec 31. Am J Physiol Endocrinol Metab. 2014. PMID: 24381003 Free PMC article.

5

The therapeutic potential of second and third generation CB₁R antagonists.

Cinar R, Iyer MR, Kunos G. Cinar R, et al. Among authors: kunos g. Pharmacol Ther. 2020 Apr;208:107477. doi: 10.1016/j.pharmthera.2020.107477. Epub 2020 Jan 9. Pharmacol Ther. 2020. PMID: 31926199 Free PMC article. Review.

6

Dual inhibition of CB₁ receptors and iNOS, as a potential novel approach to the pharmacological management of acute and long COVID-19.

Cinar R, Iyer MR, Kunos G. Cinar R, et al. Among authors: kunos g. Br J Pharmacol. 2022 May;179(10):2121-2127. doi: 10.1111/bph.15461. Epub 2021 Apr 17. Br J Pharmacol. 2022. PMID: 33769552 Free PMC article.

7

Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides.

Cinar R, Godlewski G, Liu J, Tam J, Jourdan T, Mukhopadhyay B, Harvey-White J, Kunos G. Cinar R, et al. Among authors: kunos g. Hepatology. 2014 Jan;59(1):143-53. doi: 10.1002/hep.26606. Epub 2013 Nov 18. Hepatology. 2014. PMID: 23832510 Free PMC article.

8

Peripheral cannabinoid-1 receptor blockade restores hypothalamic leptin signaling.

Tam J, Szanda G, Drori A, Liu Z, Cinar R, Kashiwaya Y, Reitman ML, Kunos G. Tam J, et al. Among authors: kunos g. Mol Metab. 2017 Oct;6(10):1113-1125. doi: 10.1016/j.molmet.2017.06.010. Epub 2017 Jun 24. Mol Metab. 2017. PMID: 29031713 Free PMC article.

9

Do endocannabinoids acting via hepatic CB-1 contribute to NAFLD and hepatic insulin resistance?

Kunos G, Jourdan T, Tam J. Kunos G, et al. J Clin Invest. 2022 Jan 4;132(1):e155330. doi: 10.1172/JCI155330. J Clin Invest. 2022. PMID: 34981780 Free PMC article. No abstract available.

10

Cannabinoid-1 Receptor Antagonism Improves Glycemic Control and Increases Energy Expenditure Through Sirtuin-1/Mechanistic Target of Rapamycin Complex 2 and 5'Adenosine Monophosphate-Activated Protein Kinase Signaling.

Liu J, Godlewski G, Jourdan T, Liu Z, Cinar R, Xiong K, Kunos G. Liu J, et al. Among authors: kunos g. Hepatology. 2019 Apr;69(4):1535-1548. doi: 10.1002/hep.30364. Epub 2019 Mar 6. Hepatology. 2019. PMID: 30506571 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

292 results

Search Page